Status:
SUSPENDED
Neuroinflammation in Patients With OCD
Lead Sponsor:
New York State Psychiatric Institute
Conditions:
Obsessive-Compulsive Disorder
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
The goal of this study is to examine whether measurements of inflammation from brain scanning and blood tests can predict how much benefit patients with obsessive-compulsive disorder (OCD) will have f...
Detailed Description
Existing evidence-based treatments for adults with obsessive-compulsive disorder (OCD), including cognitive behavioral therapy and first-line medication-based treatment, do not fully resolve symptoms ...
Eligibility Criteria
Inclusion
- 18 to 55 years old
- Principal diagnosis of Obsessive-Compulsive Disorder (OCD)
- Ongoing OCD symptoms despite current treatment with psychiatric medication
- Capacity to provide informed consent
Exclusion
- Psychiatric comorbidities that would increase risk of participation or impact research measures (e.g., suicidality)
- Medical or neurological conditions that would increase risk of participation or impact research measures
- Contraindications to an MRI or PET scan (e.g., metal implants)
- Current use of medications that may interact with study drug or impact research measures (e.g., antipsychotics, corticosteroids, immunosuppressant medications, or daily non-steroidal anti-inflammatory medications)
- Starting a new evidence-based therapy for OCD (e.g., exposure with response prevention) 4 weeks prior to study enrollment
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT04786548
Start Date
April 1 2021
End Date
August 1 2026
Last Update
November 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York State Psychiatric Institute
New York, New York, United States, 10032